Skip to main content
OpenTrials
Completed

NCT Number: NCT02572479

Evaluating the Potential of the Diet as Disease Modifier in Amyotrophic Lateral Sclerosis (JERN_ALS)

The proposed observational trial will collect substantial data concerning dietary intake documented by ALS patients complemented by the analysis of fatty acid distribution in erythrocyte lipids. Both data sets are related to disease status and progress.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Amyotrophic lateral sclerosis (ALS) is a currently incurable, multifactorial motor neuron disease characterized by upper and lower motor neuron degeneration, skeletal muscle atrophy, paralysis, and death. Multiple mechanisms caused by genetic and environmental factors proposed as responsible for ALS pathogenesis include decreased availability to neurotrophic factors, disturbances in calcium metabolism, increased neuroinflammatory status, cytoskeletal changes, mitochondrial dysfunction, dysfunction of protein degradation, glutamate excitotoxicity, apoptosis and oxidative stress.

Currently, the only available drug to treat ALS is riluzole which slightly prolongs life. Nutritional management has become more important in the treatment of ALS because body mass index and nutritional status seems to be independent, prognostic factors for survival and disease complications. Malnutrition is common in ALS, so caloric supplementation is essential. Additionally, many ALS patients self-medicate with vitamins, herbs, and other dietary supplements.

The objective of the current project is establishing the link between nutritional intake and disease status and progress. In detail, we like to assess if the improved outcomes are associated with specific nutrients, or simply the provision of excess calories. In this context, one of the most promising dietary candidates are polyunsaturated fatty acids (PUFA) and in particular the long-chain n-3 PUFA docosahexaenoic acid. This important structural component in neuronal membranes plays a role in neurogenesis and neuroprotection as well as exerts well-described anti-inflammatory effects in the brain.

The proposed observational trial will collect substantial data concerning dietary intake documented by ALS patients (Food Frequency Protocols, FFPs, periodic over 5 days) combined with the analysis of fatty acid distribution in erythrocyte lipids which reflects fatty acid distribution of the consumed fatty or oily foods (time period: approximately the last 2-3 months).

The fatty aids distribution in erythrocyte lipids as well as the nutrient intake calculated by FFPs are related to disease status and progress.

Thus, the current research activities focus on identification of dietary factors that are associated with disease progress or survival to develop beneficial interventions and therapy options.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ALS patients diagnosed according to El Escorial / Awaji criteria for ALS
  • patients should have the ability to comprehend the full nature and purpose of the study, to cooperate with the investigator, to understand verbal and written instructions, and to comply with the requirements of the entire study.

Exclusion criteria

  • patient's request or if patient compliance with the study protocol is doubtful

Treatment and study plan

Primary outcomes

  1. Clinical neurological examination

    Time frame: through study completion, an average of 1 year

    ALS functional rating scale-revised (ALSFRS-R)

    • the parameter will be assessed every three months through study completion

Secondary outcomes

  1. Nutrient intake by diet

    Time frame: through study completion, an average of 1 year

    Food Frequency Protocol (FFP) over 5 days before blood sampling (FFP originate from Prodi® 6.4 software; Nutri-Science GmbH, Freiburg, Germany).

    Data analysis via Prodi®

    • calculation food nutrient profiles originated from the 'Bundeslebensmittelschlüssel'
    • calculation of daily energy intake, intake of fat and fatty acids, carbohydrates (individual sugars, dietary fibres), protein and amino acids, vitamins and minerals, sterols, etc.
    • the parameter will be assessed every three months through study completion
  2. Fatty acid distribution in erythrocyte lipids

    Time frame: through study completion, an average of 1 year

    • marker for the fatty acid distribution of the consumed fatty or oily foods
    • reflect the fatty acid distribution of the consumed fatty or oily foods over the last 2-3 months as well as the endogenous metabolism and conversion of fatty acids
    • the parameter will be assessed every six months through study completion
  3. Blood lipids

    Time frame: through study completion, an average of 1 year

    Total cholesterol, HDL-cholesterol, LCL-cholesterol, triacylglycerides

    • the parameter will be assessed every six months through study completion
  4. Inflammatory parameter

    Time frame: through study completion, an average of 1 year

    c-reactive protein

    • the parameter will be assessed every six months through study completion
  5. Metabolic serum parameters

    Time frame: through study completion, an average of 1 year

    glycated hemoglobin HbA1C

    • the parameter will be assessed every six months through study completion
  6. Clinical neurological examination, part II

    Time frame: through study completion, an average of 1 year

    EQ5D-5L (population based QoL questionnaire)

    • the parameter will be assessed every six months through study completion

Sponsors and collaborators

Lead sponsor

University of Jena

Other

Collaborators

  • Jena University Hospital

Registry information

Official study title

Observational Study for Evaluating the Potential of Diet and Food Components as Disease Modifiers in Amyotrophic Lateral Sclerosis (JERN_ALS)

Acronym: JERN_ALS

Important dates

Study start
2015
Primary completion
2018
Study completion
2018
First posted
Oct 9, 2015
Registry last updated
Mar 7, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.